Aim: The aim of this article is to review the evidence regarding human oocyte cryopreservation by slow freezing and vitrification and to provide evidence-based clinical and laboratory guidelines on the effectiveness and safety of these technologies.
Scope: These guidelines will address the following: Stage of oocyte maturity. Methods of cryopreservation/warming. Slow controlled cooling. Vitrification. Techniques used for insemination. Ovarian stimulation regimens. The guidelines do not cover recommendations for ovarian tissue freezing or in vitro oocyte maturation (IVM).
Outcome Measures: The following outcome measures were examined: cryosurvival, fertilisation rate, cleavage rate, clinical pregnancy rate and implantation rate, health of resulting children.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14647270903132115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Homozygous Variant in HSD17B1 Identified in Women With Poor Ovarian Response.
Clin Genet
January 2025
NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, ChangSha, China.
An increasing number of patients utilizing in vitro fertilization (IVF) and assisted reproductive technology (ART) are characterized as impaired or poor ovarian responders (PORs). Owing to its unclear molecular etiology, the management of patients with age-related ovarian characteristics remains a controversial and complex clinical concern. Therefore, it is important to identify and understand the etiological causes behind POR to develop more effective and efficient management strategies for these patients.
View Article and Find Full Text PDFA Case of Familial Mediterranean Fever With Severe Attacks During Withdrawal Bleeding After Controlled Ovarian Hyperstimulation.
Cureus
December 2024
Department of Obstetrics and Gynecology, Shiga University of Medical Science, Ostu, JPN.
Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever, serositis, and arthritis. In women, FMF attacks can sometimes be triggered by the menstrual cycle. Once diagnosed, prophylactic treatment with colchicine is generally recommended.
View Article and Find Full Text PDFThe microbial communities and metabolic profiles of follicular fluid in patients with premature ovarian insufficiency.
Front Endocrinol (Lausanne)
January 2025
Department of Obstetrics and Gynecology, The Seventh Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Introduction: Premature ovarian insufficiency (POI) is a condition characterized by ovarian dysfunction occurring before the age of 40, and its etiology is multifactorial, including genetic, immunological, infectious, environmental, and iatrogenic factors, with over half of the cases remaining unexplained. Whether the microbial communities and metabolites in follicular fluid, which is the direct microenvironment for oocyte survival, are related to POI has not been reported.
Methods: In this study, Follicular fluid samples of 26 patients with POI and 27 controls with a normal ovarian reserve were collected and analyzed using 16S rDNA sequencing and untargeted metabolomics.
Enhancing oocyte competence in patients with polycystic ovarian syndrome: A microfluidic study on the effects of follicular fluid meiosis-activating sterol in in vitro oocyte maturation.
J Obstet Gynaecol Res
January 2025
Reproductive Sciences and Technology Research Center, Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Objective: To evaluate the efficacy of a microfluidic culture system supplemented with follicular fluid meiosis-activating sterol (FF-MAS) on the maturation of immature oocytes in patients with polycystic ovarian syndrome (PCOS).
Methods: A total of 438 germinal vesicle oocytes from 163 PCOS patients were included. Oocytes were divided into five groups: (1) cultured in static drops without FF-MAS, (2) cultured in static drops with FF-MAS, (3) cultured in a microfluidic device without FF-MAS, (4) cultured in a microfluidic device with FF-MAS for the first 2 h, and (5) cultured in a microfluidic device with FF-MAS for 24 h.
The first multiple center prospective study of rhFSH CTP in patients undergoing assisted reproductive technology in China.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China.
We assessed the safety and efficacy of rhFSH-CTP, a novel long-acting FSH agent, in controlled ovarian hyperstimulation for patients undergoing ART. A multi-center, open-label, randomized, positive-control, non-inferiority clinical trial was conducted. The study consisted of a phase III randomized design, with a 1:1 ratio favoring the rhFSH-CTP group over the control group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!